UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals ... This is important because there’s a clear need to find non-addictive alternatives to opioid painkillers.

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

But the medication’s modest effectiveness and lengthy development process underscore the challenges of finding new ways to ...

But the medication’s modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain. Two studies in more than 870 patients with acute pain following ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

In a recent survey commissioned by Vertex, including more than 500 healthcare providers and 1,000 patients, results suggested that both groups would prefer non-opioid options.

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...